Second Sight Medical Products (NASDAQ:EYES) and Rockwell Medical (NASDAQ:RMTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.
This is a summary of recent recommendations and price targets for Second Sight Medical Products and Rockwell Medical, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Second Sight Medical Products||0||0||1||0||3.00|
Second Sight Medical Products currently has a consensus price target of $5.00, indicating a potential upside of 198.51%. Given Second Sight Medical Products’ higher probable upside, research analysts clearly believe Second Sight Medical Products is more favorable than Rockwell Medical.
Volatility and Risk
Second Sight Medical Products has a beta of 3.07, suggesting that its share price is 207% more volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500.
Institutional and Insider Ownership
10.8% of Second Sight Medical Products shares are held by institutional investors. Comparatively, 22.2% of Rockwell Medical shares are held by institutional investors. 48.3% of Second Sight Medical Products shares are held by insiders. Comparatively, 18.2% of Rockwell Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Second Sight Medical Products and Rockwell Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Second Sight Medical Products||-418.82%||-432.45%||-232.22%|
Earnings & Valuation
This table compares Second Sight Medical Products and Rockwell Medical’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Second Sight Medical Products||$7.96 million||14.11||-$28.51 million||($0.59)||-2.84|
|Rockwell Medical||$57.30 million||3.56||-$25.92 million||($0.51)||-7.76|
Rockwell Medical has higher revenue and earnings than Second Sight Medical Products. Rockwell Medical is trading at a lower price-to-earnings ratio than Second Sight Medical Products, indicating that it is currently the more affordable of the two stocks.
Rockwell Medical beats Second Sight Medical Products on 7 of the 13 factors compared between the two stocks.
About Second Sight Medical Products
Second Sight Medical Products, Inc., together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa. The company was formerly known as Second Sight LLC. and changed its name to Second Sight Medical Products, Inc. Second Sight Medical Products, Inc. was founded in 1998 and is headquartered in Sylmar, California.
About Rockwell Medical
Rockwell Medical, Inc. operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. The company's lead drug includes Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment. It also provides Calcitriol, a generic active vitamin D injection, which is indicated for the treatment of secondary hyperparathyroidism in dialysis patients. In addition, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, Renalpure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubings, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. Its concentrated dialysate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. The company's target customers include senior and operating management of dialysis companies, dialysis service providers, nephrologists, clinic administrators, nurses, medical directors, and technical and purchasing personnel. Rockwell Medical, Inc. was founded in 1995 and is based in Wixom, Michigan.
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.